6/12
08:07 am
anvs
Annovis Bio, Inc. (NYSE: ANVS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock.
High
Report
Annovis Bio, Inc. (NYSE: ANVS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock.
6/11
08:13 am
anvs
Annovis Bio's Buntanetap Found Safe and Effective in High-Risk Alzheimer's Patients [Yahoo! Finance]
Medium
Report
Annovis Bio's Buntanetap Found Safe and Effective in High-Risk Alzheimer's Patients [Yahoo! Finance]
6/11
08:00 am
anvs
Annovis Bio’s Buntanetap Found Safe and Effective in High-Risk Alzheimer's Patients
Low
Report
Annovis Bio’s Buntanetap Found Safe and Effective in High-Risk Alzheimer's Patients
6/5
08:17 am
anvs
Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast [Yahoo! Finance]
Low
Report
Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast [Yahoo! Finance]
6/5
08:00 am
anvs
Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast
Low
Report
Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast
6/4
01:13 pm
anvs
Annovis Bio, Inc. (NYSE: ANVS) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $67.00 price target on the stock.
Medium
Report
Annovis Bio, Inc. (NYSE: ANVS) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $67.00 price target on the stock.
5/21
07:36 am
anvs
Annovis Announces New Publication in a Peer-Reviewed Journal [Yahoo! Finance]
Medium
Report
Annovis Announces New Publication in a Peer-Reviewed Journal [Yahoo! Finance]
5/21
07:30 am
anvs
Annovis Announces New Publication in a Peer-Reviewed Journal
Medium
Report
Annovis Announces New Publication in a Peer-Reviewed Journal
5/17
11:00 am
anvs
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors
Medium
Report
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors
5/16
07:02 pm
anvs
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors
Low
Report
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors
5/16
03:09 pm
anvs
The Law Offices of Frank R. Cruz Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors
Medium
Report
The Law Offices of Frank R. Cruz Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors
5/13
08:09 am
anvs
Annovis Bio, Inc. (NYSE: ANVS) had its price target lowered by analysts at HC Wainwright from $30.00 to $23.00. They now have a "buy" rating on the stock.
High
Report
Annovis Bio, Inc. (NYSE: ANVS) had its price target lowered by analysts at HC Wainwright from $30.00 to $23.00. They now have a "buy" rating on the stock.
5/13
07:46 am
anvs
Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results [Yahoo! Finance]
High
Report
Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results [Yahoo! Finance]
5/13
07:30 am
anvs
Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results
High
Report
Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results
5/9
07:40 am
anvs
Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson's Disease [Yahoo! Finance]
High
Report
Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson's Disease [Yahoo! Finance]
5/9
07:30 am
anvs
Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease
High
Report
Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease
5/6
07:39 am
anvs
Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders [Yahoo! Finance]
Low
Report
Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders [Yahoo! Finance]
5/6
07:30 am
anvs
Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders
Low
Report
Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders
5/2
04:15 pm
anvs
Annovis Bio: Alzheimer's Disease Topline Data Disappoints The Market [Seeking Alpha]
Medium
Report
Annovis Bio: Alzheimer's Disease Topline Data Disappoints The Market [Seeking Alpha]
5/2
10:16 am
anvs
Impact Of Buntanetap Trial Results On Annovis Bio Stock And Future Prospects [Seeking Alpha]
Medium
Report
Impact Of Buntanetap Trial Results On Annovis Bio Stock And Future Prospects [Seeking Alpha]
5/2
12:29 am
anvs
Annovis Bio: Alzheimer's Phase 2/3 Topline Readout Puts Future For Buntanetap Into Question [Seeking Alpha]
High
Report
Annovis Bio: Alzheimer's Phase 2/3 Topline Readout Puts Future For Buntanetap Into Question [Seeking Alpha]
4/30
08:12 am
anvs
Annovis Bio, Inc. (NYSE: ANVS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
High
Report
Annovis Bio, Inc. (NYSE: ANVS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
4/30
08:11 am
anvs
Annovis Bio, Inc. (NYSE: ANVS) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $36.00 to $26.00. They now have a "buy" rating on the stock.
High
Report
Annovis Bio, Inc. (NYSE: ANVS) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $36.00 to $26.00. They now have a "buy" rating on the stock.
4/30
05:08 am
anvs
Annovis Bio: Searching For Efficacy In Alzheimer's Disease [Seeking Alpha]
High
Report
Annovis Bio: Searching For Efficacy In Alzheimer's Disease [Seeking Alpha]
4/29
11:02 am
anvs
UPDATE 1-Annovis' Alzheimer's treatment helps improve cognition in trial [Yahoo! Finance]
Low
Report
UPDATE 1-Annovis' Alzheimer's treatment helps improve cognition in trial [Yahoo! Finance]